J&J signs $1B+ deal with the US for 100 million COVID-19 vaccine doses

The U.S. government on Aug. 5 committed more than $1 billion to Johnson & Johnson for 100 million doses of its investigational COVID-19 vaccine.

Advertisement

The first in-human trial for the vaccine candidate, Ad26.COV2.S, is currently taking place in the U.S. and Belgium. Johnson & Johnson used its AdVac technology to develop Ad26.COV2.S, which was also used to develop its Ebola, HIV, RSV and Zika vaccine candidates. 

Pending positive trial results, Johnson & Johnson plans to manufacture more than 1 billion doses throughout 2021. The U.S. has the option to buy another 200 million doses of Ad26.COV2.S later on.

More articles on pharmacy:
3 retail pharma giants disclose data breaches from break-ins: What to know
Amazon’s PillPack partners with New Jersey insurer, Prime Therapeutics
American women more likely than men to skip medication due to cost, study finds

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.